US · HOTH
Hoth Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10020
- Website
- hoththerapeutics.com
Price · as of 2024-12-31
$0.73
Market cap 13.39M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $133.25 | ||||
| 2019 | $100.00 | ||||
| 2020 | $53.75 | ||||
| 2021 | $15.25 | ||||
| 2022 | $2.43 | ||||
| 2023 | $1.30 | ||||
| 2024 | $1.09 |
AI valuation
Our deep-learning model estimates Hoth Therapeutics, Inc.'s (HOTH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.73
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| HOTH | Hoth Therapeutics, Inc. | $0.73 | 13.39M | — | — | — | — | -0.85 | 1.01 | — | -2.17 | — | 1.01 | 0.00% | — | — | -99.75% | -9559.27% | -91.21% | 0.00 | — | 9.20 | 8.52 | -258.29 | -4435.00% | — | -1739.00% | -100.42% | -8.40 | -8119.72% | 0.00% | 0.00% | 0.00% | 0.01 | 0.01 | — | -8.42 |
| ASBP | Aspire Biopharma Holdings… | $1.39 | 4.81M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| BCTX | BriaCell Therapeutics Cor… | $3.82 | 7.2M | — | — | — | — | -0.64 | 0.95 | — | 0.03 | -1.44 | 0.96 | 0.00% | — | — | -343.04% | 1683.01% | -192.49% | 0.00 | -735.71 | 5.01 | 4.63 | 0.39 | 4450.00% | — | 1632.00% | -167.26% | -7.14 | 1742.76% | 0.00% | 0.00% | 56.64% | 0.03 | 0.03 | — | -8.16 |
| CRIS | Curis, Inc. | $1.14 | 15.61M | +342% | +2% | — | — | -0.42 | -3.06 | 1.68 | -0.03 | — | -1.23 | 99.10% | -408.34% | -397.77% | -634.71% | 156.53% | -73.20% | -0.49 | -72.43 | 1.39 | 1.23 | 0.40 | -2321.00% | 883.00% | 294.00% | -215.59% | -2.08 | 139.03% | 0.00% | 0.00% | 0.00% | -0.03 | -0.03 | 0.12 | -44.91 |
| DARE | Daré Bioscience, Inc. | $1.70 | 16.19M | +12,485% | -31% | — | +2,345% | -6.18 | -4.17 | 2561.95 | -0.46 | — | -4.17 | -146110.22% | -239692.20% | -41430.90% | 73.30% | 135.85% | -18.69% | -0.22 | — | 0.85 | 0.74 | 0.61 | -8843.00% | -9965.00% | -11221.00% | 19.23% | 0.25 | -27.93% | 0.00% | 0.00% | 21.24% | -0.46 | 2.21 | 1090.66 | -14.24 |
| ENTO | Entero Therapeutics, Inc. | $2.85 | 13.58M | — | — | — | — | -0.43 | 0.13 | — | -491.36 | — | 0.14 | 0.00% | — | — | -58.82% | -0.05% | -39.13% | 0.00 | — | 3.03 | 0.01 | 1.47 | -8880.00% | — | -2842.00% | -119.84% | -0.33 | -31.51% | 0.00% | 0.00% | 0.00% | -490.90 | -0.83 | — | -2.37 |
| FBLG | FibroBiologics, Inc. Comm… | $0.33 | 13.77M | — | — | — | — | -1.01 | 3.05 | — | -0.92 | -4.28 | 3.05 | 0.00% | — | — | -419.44% | -1119.26% | -143.08% | 0.39 | -81.61 | 3.61 | 2.78 | 0.14 | 2353.00% | — | 3782.00% | -88.80% | -9.32 | -1119.73% | 0.00% | 0.00% | 0.00% | -0.98 | -0.98 | — | -9.77 |
| LEXX | Lexaria Bioscience Corp. | $0.70 | 13.51M | +3,989% | -40% | — | — | -1.57 | 6.26 | 26.52 | -1.43 | -3.89 | 6.98 | 83.20% | -1647.97% | -1686.00% | -216.06% | -846.18% | -182.65% | 0.04 | — | 2.32 | 1.56 | 0.14 | 4043.00% | 5205.00% | 10942.00% | -55.96% | -7.00 | -761.93% | 0.00% | 0.00% | 0.00% | -1.45 | -1.61 | 23.88 | -22.60 |
| PALI | Palisade Bio, Inc. | $1.77 | 263.74M | +38% | — | — | — | -0.08 | 0.16 | — | 0.59 | — | 0.16 | 0.00% | — | — | -153.55% | 1021.24% | -115.82% | 0.02 | -1238.25 | 3.24 | 3.04 | 0.67 | -6227.00% | -10000.00% | 948.00% | -1013.04% | -3.77 | 838.01% | 0.00% | 0.00% | 0.00% | 0.57 | 0.69 | — | -20.99 |
| PCSA | Processa Pharmaceuticals,… | $2.17 | 4.92M | — | — | — | — | -0.12 | 0.87 | — | -0.03 | — | 0.87 | 0.00% | — | — | -354.51% | -2381.97% | -262.87% | 0.04 | — | 1.22 | 0.78 | 0.09 | -5436.00% | — | 3945.00% | -761.08% | -7.34 | -2223.27% | 0.00% | 0.00% | 1.08% | -0.03 | -0.03 | — | -49.42 |
| PULM | Pulmatrix, Inc. | $2.99 | 10.92M | +6,325% | — | — | — | -1.34 | 1.81 | — | -0.55 | — | 1.81 | 0.00% | — | — | -80.93% | 1213.38% | -73.31% | 0.00 | — | 12.55 | 12.43 | 0.79 | -4618.00% | -10000.00% | -5112.00% | -78.71% | -16.51 | 1275.35% | 0.00% | 0.00% | 0.00% | -0.54 | -0.52 | — | -92.69 |
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
- CEO
- Robb Knie
- Employees
- 2
- Beta
- 0.54
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.73) − 1 = — (DCF, example).